Foundayo (orforglipron)
Foundayo is a daily tablet product containing orforglipron, made by Eli Lilly. Its approved use in the U.S. is weight management.
Educational information. This page does not give dosing instructions or tell you what to take. The current label and a prescriber decide that.
What Foundayo is
- Generic name
- Orforglipron
- Maker
- Eli Lilly
- Form
- Daily tablet
- U.S. approved use
- Weight management
- First U.S. approval
- 2026
How it differs from related products
Foundayo is the brand name for orforglipron, a once-daily GLP-1 pill that is a small molecule, not a peptide. That is the main difference from the Wegovy pill, which contains the peptide semaglutide.
| Product | Form | U.S. approved use | Status |
|---|---|---|---|
| Foundayo (this page) | Daily tablet | Weight management | FDA-approved for weight management |
What it is approved for
- Weight management in adults with obesity, or overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity
How it is taken
Per the label, the tablet is taken once a day, with or without food, and swallowed whole. The label says not to break, crush or chew it.
What the trials found
These are group averages from published trials of this product's weight-management use, in adults without diabetes.
ATTAIN-1
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 3,127 adults with obesity, without diabetes
- Length
- 72 weeks
- Compared with
- Placebo once daily, with a healthy diet and physical activity in all groups
- What was measured
- Average change in body weight at week 72
- Analysis approach
- Treatment-regimen estimand in the intention-to-treat population: effects regardless of treatment discontinuation
- Other results
- In the highest-dose group, 54.6% lost at least 10% of body weight, 36.0% at least 15% and 18.4% at least 20%, versus 12.9%, 5.9% and 2.8% on placebo. The manufacturer's headline figure for the highest dose is larger because it counts only participants while they were taking the drug. Compare trials only on the same estimand.
- Safety
- Stopping treatment because of side effects: 5.3% to 10.3% across the three orforglipron groups vs 2.7% with placebo. The most common side effects were gastrointestinal and mostly mild to moderate.
- Limits
- Funded by Eli Lilly. Participants did not have diabetes. The tablet strengths used in the trial were named differently in later publications and do not all match the marketed strengths, so check the Foundayo label for what is sold. Group averages do not predict one person's result.
Sources: Wharton S 2025, ATTAIN-1 trial record (NCT05869903), Foundayo (orforglipron) tablets: prescribing information
Safety
Warnings, side effects and open questions for orforglipron are on the orforglipron page. The official label is the controlling source.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Related
Sources
- Foundayo (orforglipron) tablets: prescribing information Eli Lilly and Company, on DailyMed (U.S. National Library of Medicine). Label version 7/2026. Official FDA label on DailyMed
- FDA approves orforglipron, an oral GLP-1 for adults with obesity Healio, April 1, 2026. Trade press, secondary source
- DailyMed: current FDA drug labels U.S. National Library of Medicine. Regulator
- Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1) Wharton S, et al. N Engl J Med. 2025;393(18):1796-1806. PMID 40960239. Funding: Eli Lilly. Journal article
- ATTAIN-1 trial record (NCT05869903) ClinicalTrials.gov identifier NCT05869903. Trial registry